Dezima Pharma

The Naarden, Netherlands-based venture capital company, BioGeneration Ventures (BGV), has raised €82m at the final close of its third fund, BGV III, to provide seed investments to European biotech c

Amgen Inc. came to the same conclusion as just about everyone else with a CETP inhibitor and discontinued development of AMG 899, but the company highlighted several other drug candidates during its

Dutch venture capital firm BioGeneration Ventures is looking to expand the portfolio of early-stage, human health-focused firms in its BGV III fund after securing €66m to invest. It has already invest

Before co-founding Forbion Capital Partners as a spin-out of ABN AMRO Capital Life Sciences in 2006, Slootweg was an investment director at ABN AMRO Capital Life Sciences. As Forbion's managing partne